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Monocyte hydrolases are harmful when secreted inappropriately. In this study we have investigated the
levels of one of the hydrolases, fl-hexosaminidase in patients with obstructive jaundice. These patients
showed markedly elevated plasma levels, and their monocytes show increased spontaneous secretion
and total enzyme content. The plasma enzyme levels correlate with monocyte enzyme content as well as
bile salt, and bilirubin levels, the high levels may also reflect Kupffer cell damage, as these cells clear tlie
enzyme. Compared with controls monocytes from jaundiced patients show reduced enzyme secretion
after PMA stimulation, in vitro, and unchanged secretion after zymozan stimulation. There is a
difference between plasma enzyme levels in benign and malignant patients but this does not provide a
clear distinction between the two groups. We conclude that pationts with obstructive jaundice have
increased blood level of fl-hexosaminidase, and that activated monocytes partly contribute to this
change.
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INTRODUCTION
fl-hexosaminidase (EC 3.2.1 52) is one of the lysosomal hydrolases that is critically
deficient in Tay-Sachs and Sandoff syndrome’2. This enzyme has been found to be
increased in several other diseases: e.g. diabetes mellitus3, sepsis4, enterocolitis5,
and some malignancies6’7’8’9. Hultberg
1 reported in 1981 that this enzyme was also
increased in the serum from obstructive jaundice patients and together with other
11 researchers suggested this might be due to the decreased clearance by Kupffer
cells in these disease conditions.
Monocytes are an important component of the reticuloendothelial system. This
cell population is known to secrete many substances including proteins, enzymes,
cytokines, lipid metabolites and other immune regulators. It has been shown that
monocytes/macrophages secrete lysosomal enzymes spontaneously
12 and in res-
ponse to stimuli13’14. Previous work has shown that patients with obstructive
jaundice have altered immune responses15’6’17A8. The monocyte function however
in jaundice has not yet been fully studied. The relationship between monocyte
secretion of lysosomal enzymes and plasma fl-hexosaminidase level in obstructive
jaundice is poorly understood.
In this study we have investigated the monocyte fl-hexosaminidase secretion
under stimulated and non-stimulated conditions and its relation with plasma fl-
hexosaminidase and bile salts levels.
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MATERIALS AND METHODS
Patients and Controls
Fifty eight patients with obstructive jaundice were included in the study. Twenty
nine had a cholangiocarcinoma, 7 had pancreatic carcinoma and 1 gallbladder
cancer, the remaining 21 had benign disease which was due to gallstones in 19 and a
benign biliary stricture in two. Forty-two controls were either non-jaundiced
patients admitted for elective surgery (n 32) or normal volunteers (n 10). The
patients in the control group comprised 20 with benign diseases (14 with gallstones,
5 with inguinal hernias and 1 with haemorrhoids) and 13 with malignant disease
(colon cancer with or without liver metastases). Patients with sepsis were excluded.
The median age for the jaundiced patients was 64.7y (IQR 57.3-74.8) and for the
controls 53.8y (IQR 42.5-70.5). Informed consent to participate in the study was
obtained from all the patients. Blood was taken immediately after admission,
before any procedures were carried out.
Cell Preparation
All materials were purchased from Sigma unless otherwise stated. 20mls peripheral
blood were taken into a Sterilin bottle (Sterilin, England) containing 200U heparin.
Blood was put immediately onto ice and processed, at 4C, as soon as possible
(within 60mins). Plasma was obtained after centrifugation of blood at 1500 rpm for
20 minutes it was then stored at -80C until needed. Mononuclear cells (MNC) were
obtained by Ficoll-Hypaque separation. A small portion of the resulting cell
suspension was used for non-specific esterase staining to estimate the monocyte
proportion in the MNC preparation, this was: 29% (IQR 25%-36%) in jaundice
and 27% (25%-31%) in controls. MNC’s at 2 106 were then added to a multiwell
plate (NUNC, Denmark) at 100/A/well and allowed to adhere to the plastic surface
at 37C in 5% CO2 for 60 minutes. Non adherent cells were then washed off and the
monocytes were re-suspended in RPMI 1640 with 2.0% bovine serum albumin
(BSA, fraction V, Boehringer Mannheim GmbH, Germany). Serum was avoided
in cell culture because it contains a high concentration of fl-hexosaminidase.
Cell Stimulation
Aliquots of cells in triplicate were then treated with (i) culture medium only for
estimation of spontaneous secretion, with (ii) phorbol myristate acetate (PMA) at a
concentration 5.0/g/ml, or with (iii) opsonised zymozan particles at 0.5 mg/ml
made up as follows; 10mg zymozan was heat inactivated at 100C for 10 minutes
and washed, 2.0 ml pooled human serum was added to the particles and incubated
at 37C for 30 minutes after washing 10 times at 2000 rpm for 10 minutes the
particles were re-suspended in culture medium and stored at -80C. Some cells were
also treated by 10% Triton X100 to cause the release of the total enzyme content of
the monocytes. After 4 hours culture with either medium, one of the stimulants or
with Triton the plates were centrifuged at 1000 rpm for 20 minutes. Supernatants
were harvested with a multichannel pipette and stored at -80C before analysis. Cell
viability was checked by the trypan blue exclusion test before and after experiments
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Enzyme Assay
fl-hexosaminidase was assayed using a substrate
Nitrophenol-fl-N-acetyl-glucosaminide6’19 dissolved in citrate buffer (pH 4.5) at
3.75 mM. The substrate was added to samples and incubated at 37C for 4 hours in
the case of monocyte supernatant or, because of the higher concentration of
enzyme for only 30 minutes in the case of Plasma. In both systems the reaction was
terminated by adding glycine buffer (pH 10.5). The coloured product was mea-
sured on a Titertek Multiscan (Flow, UK) with a standard filter (wavelength
405nm) and was compared with the internal nitrophenol standard. 1U enzyme per
litre is the activity to produce 1/M nitrophenol per min. Monocyte spontaneous
and stimulated enzyme secretion were expressed as a percentage of the total
enzyme content of the cell that is released by Triton treatment. Monocyte total
enzyme content is shown as Units per million monocytes.
Other Assays
Plasma bile salts were measured with a commercial kit Enzabile from Nycomed
AS., Oslo, Norway. The assay was carried out according to the manufacturers
instructions and the concentrations were calculated from the standard bile salts
provided with the kit. Plasma bilirubin, aspartate aminotransferase, alkaline
phosphatase and albumin were measured at the same time by routine laboratory
methods. The results are expressed as median (inter quartile range, IQR) and
statistical tests used were Mann-Whitney U test and Spearman rank correlation
test.
RESULTS
Monocyte fl-hexosaminidase Secretion
Spontaneous secretion
Monocytes from obstructive jaundice patients have an increased spontaneous
secretion of fl-hexosaminidase at 17.4 (14.3-21.3)% compared with only 8.1 (3.5-
14.7)% in controls, p<0.01 (secretion is expressed as a percentage of the cells’
total enzyme contents). This increase was especially marked in benign jaundiced
patients as shown in Table 1.
PMA stimulated secretion
In contrast to the spontaneous secretion, monocytes from jaundiced patients
greatly reduced their enzyme secretion after PMA stimulation to 7.9 (2.6-16.5)%
compared with 15.5 (8.3-22..0)% in controls, (p< 0.01). Analysis of the subgroups
of patients revealed that this change was even more pronounced in the malignant
patients. This data is shown in Table 2.
Zymozan stimulated secretion
Stimulation with opsonised zymozan particles caused control monocytes to secrete
more lysosomal enzyme and this is consistent with the work of others
13,14
confirming that opsonised zymozan particles are the most potent stimulator of18 W.G. JIANG AND M. C. A. PUNTIS
Table 1 Enzyme secretion is expressed as a percentage of the total quantity of enzyme released from
an equal number of monocytes by treatment with Triton X100. Increased secretion is especially high in
benign jaundiced patients
Spontaneous enzyme secretion from control and jaundiced patients
Benign Malignant p value
Control 6.4% 11.4%
(2.7-12.8)070 (7.2-19.6)%
Jaundice 32.5% 16.1%
(20.6-62.7)% (12.7-19.8)%
p value <0.01 =0.01
=0.15
<0.01
Table 2 Enzyme seretion is expressed as a percentage of the total quantity of enzyme released from an
equal number of monocytes by treatment with Triton X100. The secretion from malignant jaundiced patients
is significantly reduced compared with both controls and benign jaundiced patients
PMS stimulated lysosomal enzyme secretion from monocytes
Benign Malignant p value
Control 15.7% 15.3%
(5.8-23.5)% (11.8-20.0)%
Jaundice 10.2070 7.4070
(4.5-17.1)% (0.8-12.6)%
p value =0.17 <0.01
0.77
<0.05
monocyte lysosomal enzyme secretion. Zymozan stimulation of monocytes from
jaundiced patients showed a response similar to that in controls with 27.8 (16.8-
39.0)% in jaundice compared with 29.5 (17.3-42.8)% in controls, (p=0.77). The
responses were the same in benign and malignant disease, the data is shown in
Table 3.
Monocyte total enzyme contents
As measured in the supernatant from Triton lysed monocytes the total enzyme
content from jaundiced patients was 0.46 (0.32-0.56) U/million cells which was
higher than controls 0.28 (0.18-0.36) U/million cells with p<0.01. Analysis of
subgroups of patients showed a significant difference between the benign and
malignant jaundiced patients, but not between other groups, this data is shown in
Table 4.
Plasma -Hexosaminidase and Bile Salt Levels
fl-Hexosaminidase
The plasma enzyme levels were significantly increased in obstructive jaundice
patients, 39.7 (28.4-54.5) U/I compared with controls, 13.4 (9.5-19.7) U/I.MONOCYTE SECRETION IN JAUNDICE 19
Table 3 Enzyme secretion is expressed as a percentage of the total quantity of enzyme released from
an equal number of monocytes by treatment with Triton X100. All groups respond in the same way to
zymozan
Zymosan stimulated lysosomal enzyme secretion from monocytes
Benign Malignant p value
Control 28.07o 34.67o
(14.1-36.8)70 (17.3-42.8)7o
Jaundice 29.87o 27.77o
(15.2-47.9)% (17.0-34.9)070
p value 0.67 0.07
=0.21
=0.42
Table 4 /-Hexosaminidase is expressed as Units per million cells. The monocytes from malignant jaundice
patients release most enzyme in response to Triton X100
Total lysosomal enzyme release from monocytes
Benign Malignant p value
Control 0.26 0.34
(0.14-0.34) (0.20-0.58)
Jaundice 0.34 0.52
(0.2-0.48) (0.34-0.66)
p value =0.0.25 =0.14
=0.08
<0.01
(p<0.001). The differences between benign controls (12.2(9.5-16.7) U/l) and
benign jaundiced (31.8(28.2-47.6) U/l), and also between malignant controls
(18.9(3.7-25.5) U/I) and malignant jaundiced (46.7(30.4-63.5) U/l) all reached
statistical significance. There was also a difference between the benign and
malignant jaundiced patients, but no difference between control groups was seen.
Bile salts
As expected plasma bile salt levels in jaundiced patients, 61.5 (14.5-101.5)/M/1
were greatly increased compared with controls, 8.9 (4.8-16.5) /M/1, p<0.001.
Statistically significant differences were also seen in analysing the benign subgroup
6.2(2.0-11.9)/M/1 in control and 50.8(14.2-68.0)/M/1 in jaundice and the malig-
nant subgroup 15.8(12.3-37.6)/M/I in control and 81.3(15.3-108.2)/M/1 in jaun-
dice.
Plasma biochemistry
Plasma biochemistry from patients and controls is summarised ,in Table 5. The
controls all had values within the normal range for this institution.
The relationships between the monocyte lysosomal secretions, plasma enzyme
levels, bile salts and biochemistry in jaundice patients
As shown in Table 6, the increased monocyte total enzyme contents and decreased20 W.G. JIANG AND M. C. A. PUNTIS
Table 5
Plasma Biochemistry
Control Jaundice
Bilirubin mM/1
Alk.phos. IU/I
AST IU/I
Albumin g/1
9.0 136.0
(6.7-14.0) (51.0-265.2)
94.5 592.0
(85.2-112.0) (370.3-848.8)
20.0 74.0
(16.0-28.5) (51.0-142.0)
42.5 35.5
(40.7-44.3) (32.0-38.5)
Data expressed as median (IQR)
Table 6
The correlation coefficients between monocyte hexosaminidase activity and liver function
Spont. PMA Zymozan LPS Total Plasma
Bile salts 0.07 0.28 0.21 0.23 0.28 0.44*
Bilirubin 0.06 0.47* 0.18 0.06 0.39* 0.35*
AST 0.15 0.13 0.24 0.08 0.06 0.01
Alk. Phos. -0.06 -0.10 -0.24 0.05 0.19 0.35*
Albumin 0.16 0.19 0.23 0.14 0.18 0.03
*= Significant correlation p <0.05.
response to PMA stimulation have a close relationship with the degree of jaundice
(correlation indes r 0.39, p 0.01 and r 0.47, p< 0.01 respectively).
Plasma fl-hexosaminidase level war also positively correlated with monocyte
total enzyme contents (r=0.31), bile sale levels (r=0.44), alkaline phosphatase
(r=0.35) and bilirubin (r=0.35)
DISCUSSION
fl-hexosaminidase is one of the monocyte lysosomal hydrolases. This enzyme is
cleared from the circulation by Kupffer cells in the liver2’21, by the kidney
22 and
some other tissues. In blood however, this enzyme exists as its precursor form and
the mode of clearance of the precursor is not clear23. Hultberg in 1981 reported
that the concentration of this enzyme increased in the blood of patients with
obstructive jaundice. This enzyme has also been found to be increased in animals
after hepatectomy24, or with sepsis4. These studies suggested that the increases
were due to damaged Kupffer cell clearance rather than increased production. The
correlations between plasma fl-hexoaminidase level and bile salt levels has also
been previously reported in pati,,,; with intrahepatic cholestasis11. We confirm
from our study that the blood levels of fl-hexosaminidase are elevated in bothMONOCYTE SECRETION IN JAUNDICE 21
benign and malignant jaundiced patients. Our data also shows that plasma/3-
hexosaminidase is positively correlated with bile salt and bilirubin levels. The
plasma fl-hexosaminidase level has been reported to be a marker to distinguish
between patients with benign or malignant jaundice25. Our data only partly
supports this conclusion as there is a considerable overlap between the two groups.
Jaundiced monocytes have an increased total enzyme content (Table 4) and this
is correlated with plasma/%hexosaminidase level suggesting that monocytes contri-
bute in part to the increased plasma enzyme level in addition to the depressed
Kupffer cell clearance of the enzyme. Therefore the increased plasma /3-
hexosaminidase is not only a measure for the function of the fixed cells of the
reticuloendothelial system26’27 but also partly reflects peripheral monocyte activa-
tion. The change in monocyte total enzyme content in jaundiced patients is
different from that reported by Holdstock et al. 28, where the enzyme levels were
found to be reduced in cirrhotic patients. The changes seen here are similar to those
in the small number of jaundiced patients in Holdstock’s report.
Monocytes secrete some lysosomal enzyme spontaneously (Table 1) and
increased amounts in response to stimulation. Indeed we have shown that PMA
(Table 2) and opsonised zymozan particles (Table 3) can stimulate /3-
hexosaminidase secretion from control monocytes however PMA has an inhibitory
effect on release of enzyme from jaundiced cells (that is, a lower proportion of the
totaly enzyme content of the cell is released; although the content is higher in
jaundice). In the case of zymozan stimulation jaundice and control cells release the
same proportions of their respective totals. It is known that zymozan has its effects
on monocyte lysosomal secretion via mannose-like receptors on the cells. Our data
may suggest that the capacity for phagocytosis of these particles remains intact in
obstructive jaundice. Indeed previous work in this laboratory has shown that
monocytes from jaundiced patients phagocytose particles (bacteria and latex
beads) normally (Puntis, M.C.A. data presented at the 2nd World Congress of
HPB Surgery 1988). These results are different from some other reported
investigations
29 which may be due to the material used in the study. Phorbol
myristate acetate is a kinase C activator and its effects involve a cell surface
receptor and intracellular mechanisms3. The reason for the inhibitory effect on the
release of/%hexosaminidase from jaundiced monocytes in response to this stimulus
is not clear at present. Monocytes from jaundiced patients also show increased
spontaneous secretion of/%hexosaminidase. Two possible explanations for this are:
(i) membrane fatty acids may be modified, as it has been shown that in jaundiced
patients essential fatty acids are deficient31. The membrane fatty acids are an
important component of several cell functions involving the cell surface and
intracellular mechanisms32. We have previously reported that in vitro supplemen-
tation with n-6 fatty acids may inhibit the spontaneous secretion of this enzyme in
obstructive jaundice33. Essential fatty acids and their metabolites are involved in
the immune response
34 and therefore may play an important role in the altered
monocyte function that we report here in jaundiced patients. (ii) Monocyte
secretion of cytokines is modified in jaundiced patients. We have,already reported
that tumour necrosis factor (TNF) and interleukin-1 can stimulate monocyte
lysosomal enzyme secretion
35 and TNF release by monocytes is increased in
jaundiced patients36.
The effects in vivo of the altered lysosomal enzyme release in jaundice are not
yet clear. It is known that monocyte lysosomal enzyme may cause tissue damage in22 W.G. JIANG AND M. C. A. PUNTIS
amoebiasis of the gut
37 and inflammatory bowel disease3, also fl-hexosaminidase
from other sources such as mucosa can cause lesions in other tissues39. We suggest
that the increased spontaneous secretion in jaundice may also be harmful to
patients. In the presence of infection, for example, monocyte/macrophages may fail
to respond adequately and this again may well be harmful to patients.
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